| Literature DB >> 27739512 |
Alasdair Breckenridge1, Hans-Georg Eichler2, Jonathan P Jarow3.
Abstract
The growth of precision medicine presents challenges for the regulators of medicines, related to aspects that include the basis of evidence generation, patient involvement in the regulatory process, cost of new medicines and the need for new regulatory models. It also raises questions about the tolerance of risk, especially with early interventions for life-threatening diseases.Entities:
Mesh：
Year: 2016 PMID： 27739512 DOI： 10.1038/nrd.2016.206
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694